Multi-Cancer Early Detection Tests Show Promise in Improving Cancer Outcomes

Strategic Insights -

Researchers from Queen Mary University of London have conducted a study on the effectiveness of multi-cancer early detection (MCED) tests in improving cancer outcomes. The study aimed to estimate the effect of screening with an MCED test at different intervals on cancer stage at diagnosis and mortality endpoints. The researchers used a state-transition model to simulate the outcomes of a screening program using an MCED test added to usual care for persons aged 50-79.

Key Takeaways:

  • The study found that adding MCED test screening to usual care at any interval could improve patient outcomes.
  • Annual MCED test screening provided more overall benefit than biennial screening, preventing 370 more cancer signals detected/year/100,000 people screened and 21% fewer deaths within 5 years.
  • Biennial screening had a similar, but less substantial, impact, detecting 292 more cancer signals/year/100,000 people screened and preventing 17% fewer deaths within 5 years.
  • The study concluded that annual MCED test screening provided a better balance of benefits and harms compared to biennial screening.
  • The researchers used the following outcome measures: diagnostic yield, stage shift, and mortality.
  • The study's findings suggest that MCED test screening could be an effective strategy for improving cancer outcomes, especially when implemented annually.

Statistics:

  • 370 more cancer signals detected/year/100,000 people screened with annual MCED test screening.
  • 49% fewer late-stage diagnoses with annual MCED test screening.
  • 21% fewer deaths within 5 years with annual MCED test screening.
  • 292 more cancer signals detected/year/100,000 people screened with biennial MCED test screening.
  • 39% fewer late-stage diagnoses with biennial MCED test screening.
  • 17% fewer deaths within 5 years with biennial MCED test screening.

Sources:

  • Assessment of the impact of multi-cancer early detection test screening intervals on late-stage cancer at diagnosis and mortality using a state-transition model. BMJ Open, 2025,15(5).
  • https://doi-org.sdpl.idm.oclc.org/10.1136/bmjopen-2024-086648
  • BMJ Publishing Group.